Scenario, not FDA policy

2030 roadmap: customized cell therapy for all US patients

One plausible path for approved, customized stem cell therapies to move beyond specialist centers by 2030, and the conditions it depends on.

This is a forward-looking scenario prepared for discussion. FDA has not announced any policy that would let urgent care centers, as a class, make or give customized cell therapies.
2026–2027

Build the evidence base

More cell and gene therapy approvals under FDA's flexible CMC approach and expedited programs. Academic and industry sponsors file INDs for customized stem cell products.

2027–2028

Prove distributed manufacturing

Sponsors show that hub-and-spoke or point-of-care manufacturing gives comparable product quality across sites, inside their INDs and BLAs.

2028–2029

Qualified treatment networks

Approved products reach networks of certified centers (as CAR-T did through qualified treatment centers), with standard training, data capture and long-term follow-up.

2029–2030

Community and urgent care roles

Urgent care and community clinics act as access points: screening and referral, sample collection where a label allows, follow-up visits, and real-world data. Administering a product would depend on each product's label and any REMS.

What has to be true

  • Products approved by BLA, with labels that allow administration outside specialist centers
  • Validated, automated closed-system manufacturing with reliable potency assays
  • Payer coverage and reimbursement models for one-time, high-cost therapies
  • Trained staff, cold-chain logistics and adverse-event management at community sites
  • Interoperable registries and AI-assisted real-world evidence for long-term safety follow-up